We used continuous variable rate infusions of famotidine in eight normal volunteers under fasting conditions to raise intragastric pH to 5-0. An intragastric glass electrode continuously monitored acidity and this information was automatically computed to regulate an intravenous infusion system (Gastrojet). The computer was programmed to aim for pH 6*0, increasing and lowering infusion rates accordingly. Two regimens were compared with placebo (10 mg bolus followed by infusion or infusion of famotidine alone). Volunteers were admitted to an investigation ward and each study was preceded by a standard normal meal. Hydration was maintained with intravenous fluids. During placebo treatment the median pH was 1-5 and the pH was <5-0 for 98% of the time. All volunteers responded to famotidine but dosage requirements varied (range 41 mg to 126 mg). The median pH rose to 6*5 when infusions of famotidine followed boluses and to 6-6 when infusions alone were used -the pH was <5-0 for 20% (Ingold M440, Switzerland). The pH recording system has previously been described and validated.' A target pH is programmed and infusion rates are adjusted upwards until this value is reached. Rates are then decreased at 28 minute intervals while pH remains at or above target, but are increased after four minutes if the pH falls below target. A mark is recorded in the machines memory every time the rate is increased or decreased. Preliminary studies with the equipment had suggested that a target pH one unit higher than that actually expected should be programmed in order to limit fluctuations around the target value itself. A full validation study has been published elsewhere.6 Thus, a target of 6-0 was chosen for these studies. Famotidine, 40 ml (4 mg/ml), or placebo (normal saline) was loaded into plastic infusion bags which fit into the machine. The infusion bags were weighed before and after each study day to check on total infusion volumes.
Intravenous antisecretory agents are commonly used to limit peptic activity in the stomach by raising the gastric pH. Hitherto, regimens have been empirical and similar for all subjects. It has been shown that continuous infusions of famotidine raises the gastric pH to 5 or higher in fasted duodenal ulcer patients.' To achieve consistent responses, a higher dose of drug than is needed is infused for some patients. A new computerised infusion pump (Gastrojet, MIC, Switzerland) has been developed to circumvent this difficulty. This device registers gastric pH and adjusts the rate of drug delivery accordingly. One might envisage its use in intensive care units when attempts are made to closely control intragastric pH over prolonged periods. We have assessed the ability of this pump to infuse famotidine at rates sufficient, firstly, to raise gastric pH to 5 0 and, secondly, to maintain acidity at this value over 24 hours.
Methods
The Gastrojet consists of a small volume peristaltic pump capable of infusing agents at rates between 1 Ill/minute and 99 gtl/minute. There are 11 variable rate settings, which are programmable. Infusion rates during use are increased or decreased automatically in response to pH measurements fed back from a solid state pH recorder. The latter records pH at six second intervals from a 4 mm combined glass electrode (Ingold M440, Switzerland). The pH recording system has previously been described and validated.' A target pH is programmed and infusion rates are adjusted upwards until this value is reached. Rates are then decreased at 28 minute intervals while pH remains at or above target, but are increased after four minutes if the pH falls below target. A mark is recorded in the machines memory every time the rate is increased or decreased. Preliminary studies with the equipment had suggested that a target pH one unit higher than that actually expected should be programmed in order to limit fluctuations around the target value itself. A full validation study has been published elsewhere. 6 Thus, a target of 6-0 was chosen for these studies. Famotidine, 40 ml (4 mg/ml), or placebo (normal saline) was loaded into plastic infusion bags which fit into the machine. The infusion bags were weighed before and after each study day to check on total infusion volumes.
VOLUNTEERS
Eight healthy students (five men) participated in the study. They had normal biochemical profiles and haematology before entry and none required regular medication of any sort. 
Results
The studies were generally well tolerated, although headache was reported by four volunteers during one of the three periods. The symptom was observed during both active and placebo infusions. No other unwanted events were reported or observed. One volunteer refused to undergo a third study (placebo) as he found the procedures involved too unpleasant.
During placebo infusion, the median (range) 24 hour pH was 1-5 (1-0-2-0). Acidity was generally higher during the evening and night than during the day (Fig 1) .
The median (range) pH increased to 6-5 (6-1-6-7) and 6-6 (6-3-6 8) with primed famotidine infusion and infusion alone respectively. The mean (SD) pH was below 5 for 98% of the time during placebo, 20% (6) after primed infusions, and 16% (4) during infusion alone. Individual data are shown in Figure 2 . The vast majority of recordings below 5 0 were found during the time before drug action was measurable (Fig 1) .
Pump rates were apparently adjusted appropriately during the studies (Fig 3) . During placebo, the infusion rate was increased to the fastest and remained at this level throughout in all subjects. During active treatment the pH profiles were characterised by dips in pH at times when the infusion rate had been decreased below that needed to maintain the target value. In all cases, the rates were increased rapidly so the amount of time spent with a low pH was short. The mean (SD) amount of famotidine used was 98 (19) mg and 87 (26) mg with primed and nonprimed infusions respectively (p<003). The calculated total infused was always different from that measured by weighing and on average was 12 (3)% less.
Mean plasma famotidine values with either infusion regimen are shown in Figure 4 . During the night, the pH was satisfactorily maintained around the target, with lower infusion rates than those required during the day. Comparison with Figure 3 also shows that the lowest famotidine concentrations were measured when pumping rates were low, as expected.
Assessment of onset of action by our method showed that with a priming bolus mean onset was 45 minutes while infusion alone started at 75 minutes. This error, however, does not affect the feedback function of the system. We attempted to assess whether a priming bolus provided important additional antisecretory effects. It seems to give a small additional benefit (Fig 1) in accelerating the onset of action when famotidine is used. This finding depends on the method used to assess the onset of action. We used a statistical technique which should not be subjected to repeated testing.'0 We believe our use is justified, however, as no attempt has been made to assess the magnitude of change, simply that change has occurred. An alternative method was also used which defined the onset of action as the time when 80% or more values in any half hour were greater than or equal to pH 4. This analysis showed that the priming bolus injection delayed the onset of action! This method employs a more arbitrary definition of onset of action and as such is perhaps less powerful. We have concluded that the faster onset with a priming dose is unlikely to be important but accept that it could possibly be disadvantageous. It massive reservoir ofdrug were available for infusion. The system flexibility ensures that it is possible to limit the total dose infused as well as the maximum infusion rate. If gastric secretion were stimulated (by food for example), the infusion rate would increase to the value required or to the highest value possible depending on intragastric pH. It would not then infuse still higher doses unless it were reprogrammed. As the highest infusion rates programmed in this study were required in some subjects under basal (fasting) conditions it seems likely that much higher rates would need to be allowed if the system were to be expected to work during secretory stimulation.
Discussion
The Gastrojet system should be a powerful research tool in assessing the optimum dose of intravenous antisecretory agents used without the system. It can clearly show individual variations in response and may help to identify those patients who are particularly resistant to a given treatment. It may also be used to study the gastric secretory controlling mechanisms in response to different physiological stimuli. In clinical practice the use of this system in the intensive care unit and in gastrointestinal bleeding deserves assessment.
